Haemonetics Corporation (HAE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Haemonetics Corporation (HAE) Healthcare & Pipeline Overview

Haemonetics Corporation, founded in 1971, offers medical products and solutions for blood and plasma management. Operating through Plasma, Blood Center, and Hospital segments, the company provides automated collection systems, related disposables, and software solutions. With a $4.59B market cap, Haemonetics serves healthcare providers globally.

What Is the Investment Thesis for HAE?

Haemonetics, with a market capitalization of $4.59B and a P/E ratio of 49.06, presents a focused play on blood and plasma management solutions. The company's consistent profitability, reflected in a 7.3% profit margin and 55.7% gross margin, indicates operational efficiency. Growth catalysts include expanding its NexSys platform and increasing adoption of its hemostasis management systems in hospitals. However, potential risks include competition from other medical device companies and regulatory changes in the healthcare industry.

Based on FMP financials and quantitative analysis

HAE Key Highlights

Market Cap of $4.59B indicates substantial investor confidence in Haemonetics' market position.

• P/E ratio of 49.06 suggests that the company is trading at a premium compared to its earnings, reflecting investor expectations of future growth.
• Profit Margin of 7.3% demonstrates the company's ability to generate profit from its revenue.
• Gross Margin of 55.7% indicates efficient cost management in the production and delivery of its products and services.
• Beta of 0.36 suggests lower volatility compared to the market, potentially appealing to risk-averse investors.

Who Are HAE's Competitors?

HAE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are HAE's Key Strengths?

Specialized product portfolio in blood and plasma management.

• Established relationships with key customers.
• Integrated solutions combining hardware, software, and disposables.
• Strong regulatory expertise.

What Are HAE's Weaknesses?

Reliance on specific market segments (plasma, blood centers, hospitals).

• Potential impact from changes in healthcare regulations.
• Competition from larger medical device companies.
• Limited geographic diversification.

What Could Drive HAE Stock Higher?

Regulatory approvals for new blood management technologies in key markets.

• Expansion of the NexSys platform into new plasma collection centers.
• Increased adoption of TEG and ClotPro hemostasis systems in hospitals.
• Strategic partnerships with healthcare providers and distributors.

What Are the Key Risks for HAE?

Rich valuation — a P/E of 49.06 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $1.1M recently.
• Competition from established medical device companies.
• Changes in healthcare regulations and reimbursement policies.
• Technological obsolescence.
• Economic downturns affecting healthcare spending.
• Supply chain disruptions impacting production and distribution.

What Are the Growth Opportunities for HAE?

• Expansion of NexSys Platform: Haemonetics can drive growth by further expanding its NexSys platform, which automates the plasma collection process. The global plasma fractionation market is projected to reach $45 billion by 2028, presenting a significant opportunity for Haemonetics to increase its market share through technological innovation and strategic partnerships with plasma collection centers. This expansion includes continuous software updates and disposable improvements.
• Increased Adoption of Hemostasis Management Systems: Haemonetics can capitalize on the growing demand for advanced hemostasis management in hospitals. The global hemostasis and thrombosis testing market is expected to reach $5 billion by 2027. By promoting the TEG, ClotPro, and HAS systems, Haemonetics can enhance its presence in the hospital segment and improve patient outcomes during surgeries and critical care situations. Focus on training and integration with hospital systems is key.
• Geographic Expansion: Haemonetics has the opportunity to expand its market presence in emerging economies, where healthcare infrastructure is developing rapidly. Countries in Asia-Pacific and Latin America represent significant growth potential for blood and plasma management solutions. Tailoring products to meet local needs and establishing strategic partnerships with regional distributors will be crucial for successful market penetration.
• Strategic Acquisitions: Haemonetics can pursue strategic acquisitions to broaden its product portfolio and expand its market reach. Acquiring companies with complementary technologies or established customer bases can accelerate growth and enhance Haemonetics' competitive position. Careful due diligence and integration planning are essential for maximizing the value of these acquisitions.
• Development of New Blood Management Technologies: Investing in research and development to create innovative blood management technologies can drive long-term growth. This includes exploring new methods for blood collection, storage, and transfusion, as well as developing advanced software solutions for blood bank management. Staying at the forefront of technological advancements will enable Haemonetics to maintain its competitive edge and meet the evolving needs of healthcare providers.

What Are HAE's Competitive Advantages?

• Specialized Product Portfolio: Haemonetics offers a specialized portfolio of products and solutions focused on blood and plasma management, creating a niche market position.
• Established Customer Relationships: The company has established long-term relationships with key customers in the plasma collection, blood banking, and hospital sectors, providing a stable revenue base.
• Regulatory Expertise: Haemonetics possesses expertise in navigating the regulatory landscape for medical devices and blood products, creating a barrier to entry for new competitors.
• Integrated Solutions: The company provides integrated solutions that combine hardware, software, and disposables, offering a comprehensive value proposition to customers.

What Does HAE Do?

Founded in 1971 and headquartered in Boston, Massachusetts, Haemonetics Corporation is a healthcare company focused on providing medical products and solutions for blood and plasma management. The company operates through three key segments: Plasma, Blood Center, and Hospital. In the Plasma segment, Haemonetics offers automated plasma collection devices like the NexSys PCS and PCS2, along with related disposables and intravenous solutions. These systems are complemented by integrated information technology platforms, such as NexLynk DMS, which help plasma customers manage donors, operations, and supply chains. The Blood Center segment provides automated blood component and manual whole blood collection systems, including MCS brand apheresis equipment. This segment also offers disposable whole blood collection and component storage sets, the SafeTrace Tx blood bank information system, and BloodTrack blood management software. The Hospital segment features products like the TEG, ClotPro, and HAS hemostasis analyzer systems, which provide a comprehensive assessment of a patient's hemostasis. The TEG Manager software connects various TEG analyzers, giving clinicians remote access to test results. Additionally, the Cell Saver Elite + is an autologous blood recovery system used in various surgeries. Haemonetics markets its products through a direct sales force, independent distributors, and sales representatives, serving hospitals, blood centers, and plasma collection facilities worldwide.

What Products and Services Does HAE Offer?

• Provides automated plasma collection devices and related disposables.
• Offers integrated information technology platforms for plasma customers.
• Develops automated blood component and manual whole blood collection systems.
• Supplies disposable whole blood collection and component storage sets.
• Provides blood bank information systems and blood management software.
• Offers hemostasis analyzer systems for comprehensive assessment of a patient's hemostasis.
• Markets autologous blood recovery systems for various surgical procedures.

How Does HAE Make Money?

• Sales of automated plasma and blood collection devices.
• Recurring revenue from the sale of related disposables and intravenous solutions.
• Software licensing and maintenance fees for IT platforms and blood management systems.
• Service and support contracts for medical devices.
• Direct sales force and distribution partnerships.

What Industry Does HAE Operate In?

Haemonetics operates within the medical instruments and supplies industry, a segment driven by technological advancements, increasing healthcare expenditure, and an aging population. The market is competitive, with companies vying for market share through innovation and strategic partnerships. Haemonetics' focus on blood and plasma management positions it within a specialized niche of this broader industry.

Who Are HAE's Key Customers?

• Plasma collection centers.
• Blood banks.
• Hospitals.
• Surgical centers.
• Research institutions.

Company Profile

Haemonetics Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Christopher A. Simon. HAE has traded publicly since 1991.

Return on equity for Haemonetics Corporation stands at 11.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.1%, showing how much profit it generates from its asset base. HAE trades at a trailing price-to-earnings ratio of 49.06, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.95 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.8%, the inverse of the P/E and a quick read on earnings relative to price.

HAE Valuation & Market Position

With a $4.59B market cap, Haemonetics Corporation sits in the mid-cap segment of the market. Analyst price targets span from $85.00 to $125.00, with a consensus of $108.60. At the current price of $101.06, that implies approximately 7% upside potential. Relative to its peer group, HAE's quantitative score of 82/100 is above the peer average of 66/100.

Quarterly Financial Performance: Haemonetics Corporation

Revenue for Haemonetics Corporation came in at $339.4M during Q1 FY2027, a 2.0% contraction versus the preceding quarter. The company recorded net income of $33.0M, with diluted EPS of $0.72. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, HAE averaged $0.51 in diluted EPS.

Haemonetics Corporation's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.09 places it in the safe zone, indicating low near-term bankruptcy risk.

Haemonetics Corporation has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 4.6% above estimates on average.

Over the past six months, Haemonetics Corporation insiders filed 25 SEC Form 4 transactions — 10 sales and 15 purchases. On net that is roughly 208K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

HAE Financials

HAE Latest News

HAE Analyst Consensus

HAE MoonshotScore

HAE Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources